The Valley Desk

ArticleFuture oncology (London, England)Published

Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancer

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Bristol Myers Squibb. Affiliation source

Publication record

Type
Article
Venue
Future oncology (London, England)
Published
Subject terms
Humans; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Ipilimumab; Nivolumab; Adverse Events; First-line Treatment; Advanced Nsclc; Immuno-oncology Regimens
PubMed ID
38240151
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal